Gastric Cancer

Lung Cancer

Lung Cancer

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced&nbsp;<br /> esophageal or gastric cancer.<br /> &nbsp;

Maria Svensson, MD, Lund University, discusses associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-na&iuml;ve esophageal and gastric adenocarcinoma.<br /> &nbsp;

According to findings presented at the 2018 Gastrointestinal Cancers Symposium,&nbsp;the combination of the&nbsp;VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti&ndash;PD-L1 agent durvalumab (Imfinzi)&nbsp;demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti&ndash;PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric&nbsp;or gastroesophageal junction adenocarcinoma.<br /> &nbsp;

A look back at all the FDA news that occurred in the month of September.

Based on findings from the phase II KEYNOTE-059 study, pembrolizumab has been granted FDA approval for the treatment of patients with PD-L1&ndash;positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more&nbsp;lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses what he envisions for the future treatment landscape of gastric cancer.

MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals, has been recommended for approval by the FDA&#39;s&nbsp;Oncologic Drugs Advisory Committee (ODAC) in a 16-0 vote.

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.

In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population, which is encouraging as the indication is currently under consideration for approval with the FDA.

It&rsquo;s been a busy month at the FDA. Here&rsquo;s a look back at all the news in the oncology field to come out of the FDA during the month of May.

Pembrolizumab (Keytruda) has been granted a priority review by the FDA for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.